Neotropix Initiates Enrollment for Neuroendocrine Cancer Study
Neotropix, a clinical-stage development company focused on neuroendocrine cancer treatments, has started enrolling neuroendocrine cancer patients into an expanded clinical trial of its lead candidate, NTX-010, a tumor-selective naturally-occurring oncolytic virus.
The expansion phase of the study allows the clinical sites to enroll additional patients meeting the enrollment criteria to evaluate safety and efficacy across a range of related cancers. To date, the company has tested this clinical candidate, primarily in patients with carcinoid cancers of multiple origins, small cell cancer, including lung cancer, pancreatic islet cancer, and neuroendocrine cancers of unknown origin.
The primary objective of the clinical trial is the assessment of safety. It is anticipated that efficacy results from the expansion phase of this open-label, multi-center study will be available in 2009.
After reviewing safety data from the current Phase I dose escalation study, conducted in neuroendocrine cancer patients, and as previously defined in the on-going protocol, the study is open to recruit more patients at the highest dose planned for long-term drug development.
Neotropix also received orphan drug designation from the FDA for NTX-010 for the treatment of neuroendocrine tumors.
Peter Lanciano, CEO of Neotropix, said: “Based on Neotropix’s current clinical results and preclinical testing, this novel product has the potential to be an important new weapon for the treatment of a range of neuroendocrine cancers including small cell lung cancer, one of the most deadly cancers facing society.”